Recent advances in biomimetic nanodelivery systems for cancer Immunotherapy

Materials Today Bio, Journal Year: 2025, Volume and Issue: unknown, P. 101726 - 101726

Published: April 1, 2025

Language: Английский

A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy

Antibodies, Journal Year: 2025, Volume and Issue: 14(2), P. 35 - 35

Published: April 11, 2025

Monoclonal antibodies (mAbs) targeting various pathways in cancer therapy play crucial roles enhancing the immune system's ability to recognise and eliminate tumour cells. These therapies are designed either block inhibitory checkpoint or target specific cell markers for direct destruction. Additionally, mAbs can modulate microenvironment, enhance antibody-dependent cellular cytotoxicity, inhibit angiogenesis, further amplifying their therapeutic impact. Below is a summary of monoclonal key pathways, along with indications mechanisms action, which reviewed based on mechanisms.

Language: Английский

Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitor for treating unresectable hepatocellular carcinoma

British Journal of Hospital Medicine, Journal Year: 2024, Volume and Issue: 85(7), P. 1 - 12

Published: July 16, 2024

The combination of lenvatinib and programmed cell death protein 1 (PD-1) inhibitor has demonstrated significant efficacy in treating unresectable hepatocellular carcinoma. Our study aimed to evaluate the safety triple therapy that includes hepatic arterial infusion chemotherapy, PD-1 for

Language: Английский